Y-mAbs reports Q1 2024: U.S. DANYELZA rev up 11% to $18.6M; net loss $0.15/share

Y-mAbs Therapeutics, Inc.

2024-Q1 EPS reported -$0.15 revenue$19,931,000

U.S. DANYELZA net revenue $18.6M (+11% YoY); worldwide $19.4M (-4% YoY on international stocking shipment in Q1 2023).
Net loss $6.6M ($0.15 per share), relatively flat vs Q1 2023 loss of $6.4M.
Cash $75.7M, cash burn $2.9M in Q1; FY2024 guidance reaffirmed: rev $95-100M, cash runway into 2027.
CFO Bo Kruse to resign upon successor appointment; search firm retained.
Adium launched DANYELZA in Brazil/Mexico in April; five new U.S. accounts added in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Y-mAbs Therapeutics, Inc. updated its the quarter ended March 31, 2024 guidance (reaffirmed).

Period: the quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2024, Y-mAbs Therapeutics, Inc., announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-007047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.